Imarat
Imarat

Roche-India launches Atezolizumab for lung cancer

Mrs Lara Bezerra
6 122
Mrs Lara Bezerra, MD, Roche Products (India).

Rohit Shishodia
Roche India, a multinational healthcare company, has launched Atezolizumab for the treatment of extensive-stage small cell lung cancer (ES-SCLC) in India. The company has launched the cancer drug after it received DSGI approval for treatment of lung cancer in the country.

Atezolizumab is the first cancer immunotherapy to receive approval in India for the first line treatment of ES-SCLC when given in combination with chemotherapy.

Clinical study has shown significant improvement in the survival outcomes in the patients compared to the available chemotherapy options. The cancer immunotherapy harnesses the person’s immune system to combat cancer more effectively for better patient outcomes.

“Roche is committed to bring to India all the innovations being developed in its pipeline, to benefit patients.” said Lara Bezerra, Managing Director, Roche Products (India).

“Because of the aggressive nature, rapid growth, and early development of this metastatic disease, bringing an advanced treatment with improved survival has always been a challenge. Launching Atezolizumab is an important step for SCLC patients in India and reflects our commitment to “Doing now what patients need next,” added Bezerra.

In a clinical study ,Atezolizumab has demonstrated improved survival outcomes, comparable safety profile and improved the quality of life for the already approved indications.

Previously been approved for other two types of cancers, these cancers include Non-Small Cell Lung Cancer (NSCLC) and Urothelial Carcinoma, a type of bladder and urinary tract cancer. The Phase III IMpower133 study, showed that it has significantly improved Overall Survival (OS) and Progression-free survival (PFS) for the first time in over 20 years for patients with Extensive-stage Small cell lung cancer.


0 Comments

  1. Be first to post your comments

Your Comment

Your email address will not be published. Required fields are marked *

2+1

Back to Top